Foamix Pharmaceuticals Third Quarter 2014 Conference Call & Webcast Scheduled for Monday, November 17, 2014

November 10, 2014 at 3:04 AM EST
Rehovot, Israel, and Bridgewater, NJ – November 10, 2014 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce third quarter financial results and host a conference call and webcast on Monday, November 17, 2014.
Conference Call & Webcast
Monday, November 17, 2014 @ 8:30am Eastern/5:30am Pacific
Domestic:                                888-481-2844
International:                           719-457-2645
Conference ID:                       8757853
Replay, available until December 1, 2014
Domestic:                                877-870-5176
International:                           858-384-5517
Passcode:                                8757853
About Foamix Pharmaceuticals Ltd.
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals’ lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulations of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain "forward-looking statements" relating to future events. Forward-looking statements are based on Foamix Pharmaceuticals’ current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix Pharmaceuticals undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Contact:                                                         U.S. Investor Relations
Ilan Hadar, CFO                                             Michael Rice
Foamix Pharmaceuticals Ltd.                      LifeSci Advisors, LLC
+972-8-9316233                                            646-597-6979